Welcome to our dedicated page for TELESCOPE INNOVATIONS news (Ticker: TELIF), a resource for investors and traders seeking the latest updates and insights on TELESCOPE INNOVATIONS stock.
Telescope Innovations Corp (TELIF) delivers cutting-edge chemical process solutions and automation technologies for pharmaceutical research, sustainable battery materials, and industrial manufacturing. This page consolidates all official announcements and third-party analyses about the company's strategic developments.
Investors and industry professionals will find timely updates on financial results, technology patents, and strategic partnerships, including collaborations with leaders like Pfizer and Mettler Toledo. Track innovations in AI-driven Self-Driving Labs (SDLs) and recrystallization processes that redefine lithium extraction efficiency.
Our curated news collection covers earnings reports, product launches, and sustainability initiatives, providing insights into TELIF's role in advancing chemical manufacturing and battery material supply chains. Bookmark this page for verified updates on robotic automation advancements and North American battery material production capabilities.
Telescope Innovations (OTCQB: TELIF) announced a debt settlement on October 23, 2025, issuing a total of 689,654 common shares at a deemed price of CAD $0.29 per share.
The issuance settles CAD $100,000 of indebtedness to Jason Hein, CTO and director, via 344,827 shares, and CAD $100,000 of a secured loan via 344,827 shares. The secured loan originally provided CAD $1,200,000, bears 6.95% annual interest and matures on June 1, 2026.
Hein is a related party under MI 61-101; the company relied on exemptions to formal valuation and minority approval. All issued shares carry a statutory hold of four months and one day. Completion is subject to Canadian Securities Exchange and other regulatory approvals.
Telescope Innovations (OTCQB: TELIF) has achieved a significant breakthrough in battery recycling technology, successfully producing battery-grade lithium carbonate with >99.9% purity from recycled battery waste streams using their proprietary ReCRFT™ process.
Building on their April 2024 proof-of-concept, the company has demonstrated the ability to extract and refine lithium from complex battery waste materials. The process addresses a crucial challenge in battery recycling, as lithium represents 16% to 55% of the total metal value in spent batteries.
The company has partnered with Cellmine and the University of St Andrews for testing and validation of the recycled lithium carbonate in actual battery applications, marking an important step toward sustainable battery materials sourcing.
Telescope Innovations (OTCQB: TELIF), a leader in intelligent automation platforms for chemical process development, has appointed Vaso Vlachos as Chief Operating Officer. With over 20 years of experience in automation and analytical technology for biopharmaceutical and chemical industries, Vlachos joins from Mettler-Toledo AutoChem where she served as Global Head of Real-Time Analytics.
The company's DirectInject-LC product has doubled in sales opportunities in Q3 2025 compared to Q3 2024, with operations expanding from North America to Europe, Japan, and China. Telescope is also advancing Self-Driving Lab deployments with partners like Pfizer and developing lithium refinement technologies.
Additionally, the company granted 518,140 stock options to employees and consultants, exercisable at $0.43 until September 2, 2030.
Telescope Innovations (OTCQB: TELIF), a chemical process development automation company, has been selected to join ALTA (Arkansas Lithium Technology Accelerator), America's first lithium technology accelerator. The company will collaborate with industry leaders like Standard Lithium, Albemarle, ExxonMobil, and Chevron.
Telescope brings two key technologies to ALTA: ReCRFT™, a low-capital method for producing battery-grade lithium carbonate, and DualPure™, a process for creating lithium sulfide for solid-state batteries. ReCRFT™ has been validated with feedstocks from over 8 North American sites, while DualPure™ samples are being evaluated by battery industry groups in North America and Asia.
This strategic engagement comes as Telescope prepares for pilot-scale deployment of its technologies, with ALTA providing direct access to leading lithium producers for technical collaboration and operational validation.
Telescope Innovations (OTCQB:TELIF), a developer of advanced technologies for pharmaceutical and chemical industries, reported its Q3 2025 financial results. The company achieved revenues of CAD $1.39 million, up from CAD $1.22 million in Q3 2024, with an adjusted EBITA loss of CAD $99,466.
The quarter saw strong performance of their DirectInject-LC™ product, with doubled opportunities compared to Q3 2024 and successful expansion into Asian markets. Telescope is finalizing a Phase 1 Self-Driving Lab platform with Pfizer and has shipped its first battery-grade lithium sulfide samples to major battery industry groups, leveraging its proprietary low-temperature production process.
The company maintains strategic partnerships with Mettler Toledo, Pfizer, and Standard Lithium, positioning itself for continued growth in analytical and automation innovations.Telescope Innovations Corp (TELIF) reported Q2 2025 financial results with revenues of $1.0 million, up from $686,205 in Q2 2024, and an adjusted EBITA loss of $441,837. Expenses increased to $1.7 million from $1.3 million year-over-year.
Key operational highlights include: expansion of DirectInject-LC™ product into China through Mettler Toledo partnership; development of EasyFrit sampling filter accessory; 33% team growth supporting Self-Driving Lab development with Pfizer; successful production of >99% pure battery-grade lithium carbonate using ReCRFT™ technology; and CTO Jason Hein receiving the 2025 R.U. Lemieux Award.
The company continues to reinvest revenues for operational growth, with results aligning with management's FY 2025 targets.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) has announced its participation in the Planet MicroCap Showcase: VEGAS 2025. The event, scheduled for April 23, 2025, will feature a presentation by COO Dr. Jeffrey W. Sherman from 2:00-2:30 PM PST.
The company, which specializes in developing advanced technologies for pharmaceutical and chemical industries, will offer 1x1 investor meetings on April 24, 2025, at the Paris Hotel & Casino in Las Vegas. The presentation will be accessible via webcast.
Recent company achievements include:
- Advancement in Self-Driving Lab Deployment
- Master Collaborative Research Agreement with Pfizer
- Global distribution agreement with Mettler Toledo for DirectInject-LC™
- Frankfurt Stock Exchange listing
- CTO Professor Jason Hein's 2025 R. U. Lemieux Award
- Second Nobel Prize won by company advisor
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) provides an update on its Self-Driving Lab (SDL) technology development. SDLs combine AI, robotics, and advanced chemistry analytics to accelerate R&D processes 10-100 times faster than traditional methods.
The company has strengthened its position through a master collaborative agreement with Pfizer and becoming a Certified Systems Integrator with Universal Robots. Telescope has expanded its team by 33% over the past six months, enhancing expertise in chemistry, engineering, robotics, and AI-driven automation.
CTO Prof. Jason Hein has engaged with leading institutions including Seoul National University and Korean institutes to strengthen international partnerships. The company focuses on accelerating research in pharmaceuticals, industrial chemicals, and critical minerals, positioning itself to create value in the AI-powered scientific landscape.
Telescope Innovations Corp (CSE: TELI) (OTCQB: TELIF) has announced its listing on the Frankfurt Stock Exchange (FSE) under the ticker symbol 'J4U'. This strategic move expands the company's visibility and accessibility to European investors, complementing its existing listings on the Canadian Securities Exchange and OTCQB.
The company operates at the intersection of AI, robotics, advanced analytics, and chemical process innovation, developing intellectual property and automation tools for research and manufacturing efficiency. Telescope serves the pharmaceutical, industrial chemical, and critical materials sectors through world-class partnerships and industry-leading customers.
The FSE listing is expected to increase trading liquidity and provide greater exposure to international investors, particularly in Europe's chemical and pharmaceutical industries where the company has established commercial relationships.
FAQ
What is the current stock price of TELESCOPE INNOVATIONS (TELIF)?
What is the market cap of TELESCOPE INNOVATIONS (TELIF)?
